Pfizer inks $43 billion Seagen deal to boost cancer portfolio
Pfizer Inc on Monday struck a roughly $43 billion deal for Seagen Inc to bulk up its cancer treatment portfolio, as the drugmaker braces for a steep fall in COVID-19 product sales and loss of exclusivity for some top sellers.
Published 3 months ago · New York, United States
News Articles
More
Filters
Filters
Time & Location
Sources are mostly out of (0)